An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
暂无分享,去创建一个
K. Flaherty | M. Herlyn | M. Soengas | K. Smalley | R. Contractor | N. Haass | A. Kulp | G. E. Atilla‐Gokcumen | Douglas S. Williams | H. Bregman | E. Meggers | G. Atilla‐Gokcumen
[1] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[2] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[3] W. Cavenee,et al. Mutation and expression of the p53 gene in malignant melanoma cell lines , 1993, International journal of cancer.
[4] D A Scudiero,et al. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. , 1996, Cancer research.
[5] Hirofumi Tanaka,et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.
[6] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[7] F. Hodi,et al. Molecular genetics of familial cutaneous melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. El-Deiry,et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[9] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[10] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[11] D. Kimelman,et al. Role of Glycogen Synthase Kinase-3β in Neuronal Apoptosis Induced by Trophic Withdrawal , 2000, The Journal of Neuroscience.
[12] Kenneth M. Yamada,et al. Taking Cell-Matrix Adhesions to the Third Dimension , 2001, Science.
[13] Yolande F M Ramos,et al. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. , 2001, Cancer research.
[14] C. Cordon-Cardo,et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. , 2001, Cancer research.
[15] M. Herlyn,et al. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development , 2001, Oncogene.
[16] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[17] R. Bernards,et al. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.
[18] Sophie Lelièvre,et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. , 2002, Cancer cell.
[19] A. Gudkov,et al. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53 , 2003, Oncogene.
[20] D. Green,et al. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. , 2003, Cancer cell.
[21] Ling Song,et al. Glycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53* , 2003, Journal of Biological Chemistry.
[22] A. Sehon,et al. Short hairpin RNA and retroviral vector-mediated silencing of p53 in mammalian cells. , 2004, Biochemical and biophysical research communications.
[23] Douglas S. Williams,et al. An organometallic inhibitor for glycogen synthase kinase 3. , 2004, Journal of the American Chemical Society.
[24] Michel Goedert,et al. GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.
[25] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[26] J. Cheng,et al. Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.
[27] M. Herlyn,et al. Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics , 2005, Annals of the New York Academy of Sciences.
[28] C. Blattner,et al. Glycogen Synthase Kinase 3-Dependent Phosphorylation of Mdm2 Regulates p53 Abundance , 2005, Molecular and Cellular Biology.
[29] E. White,et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.
[30] O. Pluquet,et al. Endoplasmic Reticulum Stress Accelerates p53 Degradation by the Cooperative Actions of Hdm2 and Glycogen Synthase Kinase 3β , 2005, Molecular and Cellular Biology.
[31] Eric Brown,et al. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. , 2005, The American journal of pathology.
[32] E. Liu,et al. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. , 2005, Cancer research.
[33] J. C. Ghosh,et al. Activation of p53-Dependent Apoptosis by Acute Ablation of Glycogen Synthase Kinase-3β in Colorectal Cancer Cells , 2005, Clinical Cancer Research.
[34] Douglas S. Williams,et al. Switching on a signaling pathway with an organoruthenium complex. , 2005, Angewandte Chemie.
[35] G. Wahl,et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.
[36] G. Wahl,et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.
[37] O. Myklebost,et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[38] Keith T Flaherty,et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.
[39] Eric Meggers,et al. Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. , 2006, Journal of the American Chemical Society.